PolyTherics, a biopharmaceutical spin-out company from Imperial College London and the London School of Pharmacy, announced that it has secured £350,000 in funding from the Technology Strategy Board. The award, one of the first since the Technology Strategy Board assumed responsibility for the government’s collaborative research and development programme, will enable PolyTherics to work with Avecia Ltd, a leading contract development organization and manufacturer of biopharmaceuticals. The companies will collaborate on a two year project worth over £800,000 to develop new systems for the production of therapeutic antibody fragments that could ultimately lead to widespread availability of effective, low cost drugs for diseases such as, cancer, rheumatoid arthritis, irritable bowel syndrome and macular degeneration.
